Tamoxifen treatment of myocardial infarcted female rats exacerbates scar formation

Pflugers Archiv European Journal of Physiology

Volumn 454, Issue 3, 2007, Pages 385-393

  Geraldes, Pedro ^a,b   Gosselin, Hugues ^a   Tanguay, Jean François ^a,b   Clément, Robert ^a   Calderone, Angelino ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Heart; Ischemia; Reparative fibrosis; Vessels

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY DIAMETER; ARTICLE; BODY WEIGHT; CAPILLARY; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DISEASE EXACERBATION; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART RIGHT VENTRICLE; HEART WEIGHT; IN VITRO STUDY; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RAT; SCAR FORMATION; SYSTOLE; UTERUS WEIGHT;

ACTINS; ANIMALS; ANTIGENS, CD; ATRIAL NATRIURETIC FACTOR; CADHERINS; CICATRIX; CORONARY VESSELS; FEMALE; MYOCARDIAL INFARCTION; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34248349002     PISSN: 00316768     EISSN: 14322013     Source Type: Journal    
DOI: 10.1007/s00424-007-0215-5     Document Type: Article

References (32)

1. Aoki M, Morishita R, Taniyama Y, Kida I, Moriguchi A, Matsumoto K, Nakamura T, Kaneda Y, Higaki J, Ogihara T (2000) Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets. Gene Ther 7:417-427
2. Barrett-Connor E, Grady D (1998) Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 19:55-72
3. Clarke SC, Schofield PM, Grace AA, Metcalfe JC, Kirschenlohr HL (2001) Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis. Circulation 103:1497-1502
4. Dodds ML, Kargacin ME, Kargacin GJ (2001) Effects of anti-oestrogens and beta-estradiol on calcium uptake by cardiac sarcoplasmic reticulum. Br J Pharmacol 132:1374-1382
5. Drapeau J, El-Helou V, Clement R, Bel-Hadj S, Gosselin H, Trudeau LE, Villeneuve L, Calderone A (2005) Nestin-expressing neural stem cells identified in the scar following myocardial infarction. J Cell Physiol 205:51-62
6. (+) neural stem cells and fibres were detected in the normal and damaged rat myocardium. Hypertension 46:1219-1225
7. Herrington DM, Reboussin DM, Klein KP, Sharp PC, Shumaker SA, Snyder TE, Geisinger KR (2000) The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Control Clin Trials 21:257-285
8. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu CR, Liu CH, Azen SP; Estrogen in the Prevention of Atherosclerosis Trial Research Group (2001) Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 135:939-953
9. Hugel S, Reincke M, Stromer H, Winning J, Horn M, Dienesch C, Mora P, Schmidt HH, Allolio B, Neubauer S (1999) Evidence against a role of physiological concentrations of estrogen in post-myocardial infarction remodelling. J Am Coll Cardiol 34:1427-1434
10. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280:605-613
11. Lee TH, Chuang LY, Hung WC (2000) Induction of p21WAF1 expression via Sp1-binding sites by tamoxifen in estrogen receptor-negative lung cancer cells. Oncogene 19:3766-3773
12. Macgregor JI, Jordan VC (1998) Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 50:151-196
13. Marson LP, Kurian KM, Miller WR, Dixon JM (2001) The effect of tamoxifen on breast tumour vascularity. Breast Cancer Res Treat 66:9-15
14. Mcdonald CC, Stewart HJ (1991) Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 303:435-437
15. Mcdonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ (1995) Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ 311:977-980
16. Meoli DF, Sadeghi MM, Krassilnikova S, Bourke BN, Giordano FJ, Dione DP, Su H, Edwards DS, Liu S, Harris TD, Madri JA, Zaret BL, Sinusas AJ (2004) Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest 113:1684-1691
17. A receptor antagonist therapy: absence of cardiac hypertrophy and fibrosis. Br J Pharmacol 136:685-692
18. Mercier I, Mader S, Calderone A (2003) Tamoxifen and ICI 182,780 negatively influenced cardiac cell growth via an estrogen receptor-independent mechanism. Cardiovasc Res 59:883-892
19. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M (1993) Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 328:1069-1075
20. Nguyen QT, Cernacek P, Sirois MG, Calderone A, Lapointe N, Stewart DJ, Rouleau JL (2001) Long-term effects of nonselective endothelin A and B receptor antagonism in postinfraction rat. Circulation 104:2075-2081
21. Nguyen QT, Colombo F, Clement R, Gosselin H, Rouleau JL, Calderone A (2003) AT1 receptor antagonist therapy preferentially ameliorated right ventricular function and phenotype during the early phase of remodelling post-MI. Br J Pharmacol 138:1485-1494
22. Patten RD, Pourati I, Aronovitz MJ, Baur J, Celestin F, Chen X, Michael A, Haq S, Nuedling S, Grohe C, Force T, Mendelsohn ME, Karas RH (2004) 17β-Estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phosphoinositide-3 kinase/AKT signalling. Circ Res 95:692-699
23. Pham-Dang ML, Clement R, Mercier I, Calderone A (2003) Comparative effects of tamoxifen and angiotensin II type-1 receptor antagonist therapy on the hemodynamic profile of the ovariectomized female rat. Can J Physiol Pharmacol 81:915-919
24. Reis SE, Costantino JP, Wickerham DL, Tan-Chiu E, Wang J, Kavanah M (2001) Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. J Natl Cancer Inst 93:16-21
25. Ren J, Hintz KK, Roughead ZK, Duan J, Colligan PB, Ren BH, Lee KJ, Zeng H (2003) Impact of estrogen replacement on ventricular myocyte contractile function and protein kinase B/Akt activation. Am J Physiol Heart Circ Physiol 284:H1800-H1807
26. Rutqvist LE, Mattsson A (1993) Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85:1398-1406
27. Smith PJ, Ornatsky O, Stewart DJ, Picard P, Dawood F, Wen WH, Liu PP, Webb DJ, Monge JC (2000) Effects of estrogen replacement on infarct size, cardiac remodeling, and the endothelin system after myocardial infarction in ovariectomized rats. Circulation 102:2983-2989
28. Suzuki K, Murtuza B, Smolenski RT, Sammut IA, Suzuki N, Kaneda Y, Yacoub MH (2001) Cell transplantation for the treatment of acute myocardial infarction using vascular endothelial growth factor-expressing skeletal myoblasts. Circulation 104:I207-I212
29. Thorin E, Pham-Dang M, Clement R, Mercier I, Calderone A (2003) Hyper-reactivity of cerebral arteries from ovariectomized rats: therapeutic benefit of tamoxifen. Br J Pharmacol 140:1187-1192
30. Wagner EM, Gallagher SJ, Reddy S, Mitzner W (2003) Effects of tamoxifen on ischemia-induced angiogenesis in the mouse lung. Angiogenesis 6:65-71
31. Wenger NK (1997) Coronary heart disease: an older woman's major health risk. BMJ 315:1085-1090
32. Writing Group For The Women Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288:321-333